1179 related articles for article (PubMed ID: 32796045)
21. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
22. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
24. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
25. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
26. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
27. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
Misra DP; Agarwal V; Gasparyan AY; Zimba O
Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
[TBL] [Abstract][Full Text] [Related]
28. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
29. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Rivera DR; Peters S; Panagiotou OA; Shah DP; Kuderer NM; Hsu CY; Rubinstein SM; Lee BJ; Choueiri TK; de Lima Lopes G; Grivas P; Painter CA; Rini BI; Thompson MA; Arcobello J; Bakouny Z; Doroshow DB; Egan PC; Farmakiotis D; Fecher LA; Friese CR; Galsky MD; Goel S; Gupta S; Halfdanarson TR; Halmos B; Hawley JE; Khaki AR; Lemmon CA; Mishra S; Olszewski AJ; Pennell NA; Puc MM; Revankar SG; Schapira L; Schmidt A; Schwartz GK; Shah SA; Wu JT; Xie Z; Yeh AC; Zhu H; Shyr Y; Lyman GH; Warner JL;
Cancer Discov; 2020 Oct; 10(10):1514-1527. PubMed ID: 32699031
[TBL] [Abstract][Full Text] [Related]
30. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
31. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
[TBL] [Abstract][Full Text] [Related]
32. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
33. [The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Gadebusch Bondio M; Marloth M
NTM; 2020 Jun; 28(2):219-225. PubMed ID: 32399903
[TBL] [Abstract][Full Text] [Related]
34. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
35. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.
Faraone I; Labanca F; Ponticelli M; De Tommasi N; Milella L
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202656
[TBL] [Abstract][Full Text] [Related]
36. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.
Crowson CS; Matteson EL; Myasoedova E; Michet CJ; Ernste FC; Warrington KJ; Davis JM; Hunder GG; Therneau TM; Gabriel SE
Arthritis Rheum; 2011 Mar; 63(3):633-9. PubMed ID: 21360492
[TBL] [Abstract][Full Text] [Related]
37. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Marto N; Monteiro EC
Acta Med Port; 2020 Jul; 33(7-8):500-504. PubMed ID: 32425152
[TBL] [Abstract][Full Text] [Related]
38. Potential therapeutic agents against COVID-19: What we know so far.
Lu CC; Chen MY; Lee WS; Chang YL
J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
[TBL] [Abstract][Full Text] [Related]
40. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Li C; Wang L; Ren L
Virus Res; 2020 Sep; 286():198073. PubMed ID: 32592817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
